Marker Therapeutics Inc (MRKR)

[MDtoB22]

With regards to the Pancreatic cancer trial, the recent ASCO abstract provides no quantitative data respective of time. These clinical responses and stabilizations will be more significant if they are durable. Even a few months beyond expected survival could be a world of difference. Say a patient was expected to live for 10 months but survived for 15. It could be written as a 50% improvement in overall survival compared to the historical survival rate of FOLFIRINOX alone. Now extrapolate that out on a broad scale using all of the data points available and you have your bottom line. As the data matures, it will give us a clearer picture of possible efficacy trends.